The National Cancer Institute’s Natural Products Antineoplastic Development Program
- 1 January 1980
- book chapter
- Published by Springer Nature
- Vol. 70, 21-44
- https://doi.org/10.1007/978-3-642-81392-4_3
Abstract
The present Natural Products Antineoplastic Development Program of the National Cancer Institute is reviewed, and the potential new anticancer agents being developed in each of the three natural products programs, fermentation, plant, and animal, are discussed [2, 5].Keywords
This publication has 10 references indexed in Scilit:
- Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from NocardiaNature, 1977
- Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase.The Journal of Antibiotics, 1976
- New antitumor antibiotics, aclacinomycins A and B.The Journal of Antibiotics, 1975
- Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysentericaThe Journal of Organic Chemistry, 1973
- Tumor inhibitors. LXXIV. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordiiJournal of the American Chemical Society, 1972
- Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatusJournal of the American Chemical Society, 1972
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971
- Structures of harringtonine, isoharringtonine, and homoharringtonineTetrahedron Letters, 1970
- A NEW ANTIBIOTIC, MACROMOMYCIN, EXHIBITING ANTITUMOR AND ANTIMICROBIAL ACTIVITYThe Journal of Antibiotics, 1968